Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
It can occur at any age and the earlier the onset, the more serious is the long-term damage, dysfunction and failure of various organs due to the chronic hyperglycemia with diabetes mellitus patients having <10 year in life span compared to non-DM patients.
Type 1 DM patients have complete insulin deficiency due to beta-cell destruction. It may be immune-mediated or idiopathic. More commonly occurs in children 7-15 year of age, but may occur at any age.
Type 2 DM patients have insulin resistance and relative insulin deficiency.
Neonatal DM is hyperglycemia that occurs in the first 6 months of life.
The glucagon-like peptide 1 (GLP-1) agonist liraglutide can bring sugar levels under control in children with type 2 diabetes (T2D) when added to metformin with or without basal insulin, although such benefit is gained at the expense of an increased frequency of gastrointestinal adverse events (AEs), according to the results of the phase III Ellipse Trial.
A 26-week regimen of liraglutide effectively improved glycaemic control in adolescents with type 2 diabetes (T2D) who had inadequate response to metformin, according to the results of the phase III Ellipse* trial presented as a poster at the recent Pediatric Academic Societies meeting (PAS 2019).
The use of a hybrid closed-loop insulin pump, which has shown promise in improving glycaemic outcomes in adolescents and adults with type 1 diabetes, may also be beneficial in children, according to a study presented at ENDO 2018.
Intranasal delivery of dry powder glucagon in paediatric type 1 diabetes (T1D) patients with moderate to severe hypoglycaemia appears to induce recovery over half an hour, with the rise in blood glucose occurring within 15 minutes, according to a study presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017).
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Autoantigen specific therapy with alum-GAD, an investigational “vaccine” against type 1 diabetes (T1D), did not delay or prevent development of the disease in children aged 4–18 years compared with placebo injections in a small study presented at the ADA 2017 Scientific Sessions in San Diego, California, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS JPOG - Malaysia digital copy today!
Baseline body mass index (BMI) and, to a lesser extent, school socioeconomic status are associated with subsequent weight status in schoolchildren, according to a study. Lifestyle behaviours show a lower effect as compared with prior BMI, but children with a healthier lifestyle have a reduced risk of overweight and obesity at follow-up.
Use of electronic vapour products (EVP), or vaping, has been associated with an increased likelihood of engaging in sexual and substance-use risk behaviours among US teenagers, according to data from the 2017 National Youth Risk Behaviour Survey presented at the Paediatric Academic Societies (PAS) 2019 Meeting.
Parenteral antibiotic therapy duration for bacteraemic urinary tract infection (UTI) in young infants may be safely shortened, according to a recent study showing that recurrence and readmission or emergency department revisitation rates are comparable between a ≤7-day and a longer therapy course.